Histone deacetylases (HDACs) influence many cellular processes, including the modulation of signal transducer and activator of transcription activity (STAT) in response to interferon (IFN). To identify genetic markers that help optimize the IL-28B prediction of chronic hepatitis C (CHC) sustained virological response (SVR), we evaluated 27 single-nucleotide polymorphisms (SNPs) in HDAC1-11. Three SNPs, rs3778216, rs976552 and rs368328 in HDAC2, HDAC3 and HDAC5, respectively, were independently associated with SVR (Po0.05). The addition of these three HDAC's SNPs to the IL-28B predictive model (area under the curve (AUC) ¼ 0.630) rendered an important improvement of AUC-receiver operating characteristic value (AUC ¼ 0.747, P ¼ 0.021). Chi-squared Automatic Interaction Detector (CHAID) analysis denoted the significance of the rs3778216 C/C genotype in identifying a group of good responders despite carrying IL-28B T allele (79.2% of SVR), whereas HDAC5 G allele characterized a subgroup with poor response rate (25.5%). However, HDAC3 rs976552 did not display a relevant role for the hierarchical classification of patients. Variables related to SVR in hepatitis C virus genotype 1 (HCV-1) cohort were the same of those obtained for the overall population. Interestingly, in non-HCV-1 patients (n ¼ 56) the HDAC2 C/C genotype was the unique predictive variable related to SVR (AUC ¼ 0.733, Po0.007). Thus, these preliminary results suggest the potential usefulness of combined IL-28B and HDAC genotyping for the CHC patients' classification by likelihood of an SVR.
INTRODUCTION
Chronic hepatitis C (CHC) affects a significant percentage of the world's population and is a leading cause of liver fibrosis and hepatocellular carcinoma (HCC). 1 Notably, patients who are infected with hepatitis C virus (HCV) experience significant differences in disease progression and response to antiviral combination therapy. 2, 3 HCV genotype and certain interindividual genetic variants in immune response genes, such as IL-28B, HLAs and interferon (IFN)-stimulated genes (ISGs), have been implicated in the achievement of a sustained virological response (SVR) to combination treatment in CHC patients. [4] [5] [6] [7] Post-translational modification of proteins regulates transcription and cell signaling, altering protein structure and function. 8 Of all reversible post-translational modifications, such as phosphorylation, methylation and ubiquitination, histone acetylation governs the stability of chromatin and controls the accessibility of transcription factors to promoters. This dynamic process is orchestrated by the antagonistic effects of two families of proteins-histone acetyltransferases and histone deacetylases (HDACs)-whose expression and activity must be strictly regulated, as an imbalance in acetylation can alter the expression of many genes. 9, 10 Although HDACs are commonly considered transcriptional repressors of genes involved in cellular differentiation, proliferation, migration and apoptosis, the acetylation of molecules other than histones, such as transcriptional factors, modulates their activity and, consequently, the expression of target genes. 11, 12 This paradoxical mechanism constitutes a general regulatory system for many acutely induced genes, such as ISGs, which are upregulated instead of repressed by HDACs. [13] [14] [15] Thus, CHC combination treatment might be affected by genetic variants that alter the expression and function of HDACs.
Further, recent reports have implicated HDAC activity in the progression of chronic inflammatory diseases and HCC, identifying certain single-nucleotide polymorphisms (SNPs), copy number gains and aberrant expression of HDACs as risk factors of HCC development. [16] [17] [18] [19] In addition, HDAC inhibitors have also been demonstrated to be valuable pharmacological tools for cancer therapy. 20 On the basis of this evidence and the wide range of HDAC activities on gene expression and post-translational regulation, we aimed to examine the effects of interindividual genetic variations in HDACs on the achievement of an SVR to pegylated-IFN plus ribavirin combination therapy. To this end, SNPs in the HDAC1-11 genes were selected and analyzed in 285 CHC patients, finding preliminary evidences of an improvement of the IL-28B SVR predictive value by genotyping particular SNPs in HDACs.
RESULTS
Clinical and genetic characteristics associated with SVR Viral genotype (non-1), age (p40 years), baseline viral load (p6 Â 10 5 IU ml
) and GPT and GGT levels (p40 and p30 U l À 1 , 1 respectively) were significantly associated with SVR (Po0.05; Table 1 ). The genotype frequencies of each SNP and its association with outcomes of combination therapy are detailed in Supplementary  Table 1 . Genotype frequencies of these polymorphisms followed Hardy-Weinberg equilibrium, except for rs895808 in HDAC4 (P ¼ 0.015, Supplementary Table 1) .
As reported, the C/C genotype of rs12979860 in IL-28B was linked significantly to the achievement of an SVR in the studied cohort consisting of 285 CHC patients (Table 2) . Rs3778216 in HDAC2, rs976552 in HDAC3 and rs368328 in HDAC5 were also related to treatment outcome. As shown in Table 2 , carriers of the C/C genotype of HDAC2 (rs3778216) were more likely to achieve an SVR than those with the T allele (P ¼ 0.009). Moreover, the G allele of rs976552 in HDAC3 was linked to a favorable virological response (P ¼ 0.008). Further, CHC patients who carried the G allele of rs368328 (HDAC5) responded worse to combination therapy than those with the A/A genotype (P ¼ 0.011).
Because HCV-1 patients were less likely to achieve an SVR than those with other viral genotypes, we examined the influence of these SNPs on SVR in this subgroup ( Table 2) . As observed for the overall population, the C/C genotype of IL-28B correlated with higher SVR rates (P ¼ 3.5 Â 10
), as did the G allele of rs976552 in HDAC3 (P ¼ 0.036) and the A/A genotype of rs368328 in HDAC5 (P ¼ 0.014). The same trend was displayed by the rs3778216 C/C genotype of HDAC2 (P40.05).
The IL-28B C/C genotype showed a significant association with SVR (P ¼ 0.03) in our cohort of non-HCV-1 patients consisting of 56 subjects, which was more prominent for the rs3778216 C/C genotype of HDAC2 (P ¼ 0.002; Table 2 ).
Further analysis revealed a significant association between the HDAC2 CAAT haplotype (comprising rs9481408, rs2243356, rs13203445 and rs3778216) and the failure to respond (P ¼ 0.02). In addition, the HDAC3 GGC haplotype (rs1421896, rs976552 and rs2530223) effected higher SVR rates than the most common haplotype (P ¼ 0.05). In contrast, none of the HDAC5 haplotypes was linked to SVR (Supplementary Table 2) .
By multivariate logistic regression analysis, we noted a link between baseline viral load (p6 Â 10 5 IU ml À 1 ), age (p40 years), IL-28B (rs12979860), HDAC2 (rs3778216), HDAC3 (rs976552) and HDAC5 (rs368328) with SVR ( Figure 1a) .
A subsequent receiver operating characteristic (ROC) analysis (Table 3 ) demonstrated IL-28B polymorphism as the highest predictive (area under the curve (AUC) ¼ 0.630, Sen ¼ 43% and Sp ¼ 83%), followed by HDAC2 rs3778216, HDAC5 rs368328 and HDAC3 rs976552 (Table 3) . Nonetheless, the model that comprised Abbreviations: CHC, chronic hepatitis C; CI, confidence interval; FS, pre-treatment fibrosis stage classified by METAVIR score; GGT, gamma glutamyl transpeptidase; GOT, glutamyl oxaloacetic transaminase; GPT, glutamyl pyruvic transaminase; M, men; Med, median; NR, non-responders; NS, not significant; OR, odds ratio; SVR, sustained virological response; VG, viral genotype; VL, viral load; W, women. P-value was calculated by means of univariate logistic regression analysis. VL, GOT, GPT and GGT are baseline serum levels. In each variable are indicated the number of patients with data available.
the three HDAC SNPs revealed a higher AUC value (AUC ¼ 0.679) than that obtained for the IL28-B alone ( Figure 1b) . Interestingly, the model with all genetic variants (IL-28B þ HDAC2-3-5) had an AUC of 0.747, which significantly improved the sensitivity and predictive value of IL-28B (P ¼ 0.021) in spite of a mild decrease of specificity (69%). Further, the multivariate logistic regression model with all clinical and genetic covariates had the highest sensitivity (75%) and predictive value (AUC ¼ 0.776), being significantly better than IL-28B model AUC (P ¼ 0.003; Figure 1b ).
In the analysis of CHC patients, stratified by viral genotype, the results for HCV-1 individuals were similar compared with the overall population, wherein baseline viral load, age and the genetic variants in IL-28B, HDAC2, HDAC3 and HDAC5 above were associated independently with SVR (Figures 1c and d and Table 3 ). Despite the fact that IL-28B and HDAC2 were related to SVR (Table 2) , only rs3778216 in HDAC2 remained predictive by multivariate regression analysis (P ¼ 0.007) for the 56 non-HCV-1 subjects studied; of note, this variant had a notable power in predicting an SVR for non-HCV-1 patients, as ROC analysis revealed (AUC ¼ 0.733, Table 3 ).
Additive effect of HDACs and IL-28B polymorphisms on SVR On the basis of our results, we examined the additive effects of genetic variants in HDACs and IL-28B with regard to SVR achievement. Patients who carried the C/C genotype of rs3778216 (HDAC2) had higher SVR rates in both IL-28B genotype groups (C/C and T carriers), more so in those who harbored the favorable IL-28B genotype (P ¼ 0.028). Patients with the IL-28B and HDAC2 C/C genotypes had elevated response rates (90%, P ¼ 2.4 Â 10
) compared with carriers of both unfavorable alleles (38%; Figure 2a ).
Similarly, patients with the G allele of rs976552 (HDAC3) had improved SVR rates in both IL-28B genotypes compared with HDAC3 A/A carriers. Nevertheless, subjects with both positive genetic variants responded significantly better to IFN-based therapy than those with the risk alleles (P ¼ 1.4 Â 10 À 5 ; Figure 2b ). Although the HDAC5 A/A genotype (rs368328) improved the response to treatment in both IL-28B groups, patients with the T allele of IL-28B were more favorably affected, 60% of whom attained an SVR (P ¼ 0.005). This pattern was more substantial for both favorable genotypes compared with unfavorable ones (P ¼ 2.7 Â 10 À 5
; Figure 2c ).
Decision tree model On the basis of these results, a Chi-squared Automatic Interaction Detector (CHAID) algorithm was used to establish a hierarchical prediction model of response to combination treatment ( Figure 3 ). According to logistic regression, CHAID analysis rendered Abbreviations: AUC, area under the curve; BVL, baseline viral load; CHC, chronic hepatitis C; CI, confidence interval; HCV, hepatitis C virus; HDAC, histone deacetylase; IL, interleukin; ROC, receiver operating characteristic; s.e., standard error; Sen, sensitivity; Sp, specificity; SVR, sustained virological response. *P ¼ 0.021, **P ¼ 0.003 and ***P ¼ 0.007 vs IL-28B model.
HDACs and IL-28B
SNPs on CHC therapy response R Ló pez-Rodríguez et al
HDACs and IL-28B SNPs on CHC therapy response R Ló pez-Rodríguez et al
rs12979860 in IL-28B as the strongest predictor of response. In addition, HDAC2 (rs3778216) genotype was a robust factor in predicting treatment outcome in patients with the IL-28B C/C genotype. Thus, characterizing the IL-28B and HDAC2 genotypes allowed us to identify a subgroup of patients with a high response rate (90%, corrected P-value (P c ) ¼ 0.017). Conversely, the CHAID analysis identified age as a key factor of SVR in patients with the IL-28B T allele (P c ¼ 0.004). Thus, 64.7% of subjects aged under 40 years had an SVR vs 39.4% of those patients older. Notably, nearly 80% of patients aged under 40 years achieved an SVR if they carried the HDAC2 C/C genotype, despite harboring the unfavorable IL-28B T allele (P c ¼ 0.042).
It is worth noting that this analysis revealed a subgroup of patients with the lowest rate of response (25.5% of the overall population), comprising subjects with the IL-28B T allele aged above 40 years and with the G allele of rs368328 in HDAC5 (P c ¼ 0.003). The rs976552 in HDAC3 and baseline viral load were finally discarded by CHAID analysis from the decision tree model.
DISCUSSION
The lack of response of an important percentage of CHC patients to combination treatment, its related adverse events and elevated costs have demanded the development of new prognostic markers that can help clinicians adjust CHC therapy. 3, 21 Indeed, CHC patients who fail to respond are more vulnerable to cirrhosis and HCC as a consequence of disease progression.
Although previous studies have described certain genetic variants as predictors of CHC combination treatment outcome, [4] [5] [6] [7] the weak likelihood of response in specific subgroups of patients, that is, IL-28B T allele carriers, requires further identification of host and viral response factors. Even more, additional response markers that improve the IL-28B predictive value might help assign the more suitable treatment, peg-IFN plus ribavirin or novel direct antiviral agents.
The demonstrated regulation of the IFN pathway by HDACs, in addition to their epigenetic modulation role, renders them attractive combination treatment targets to further study. 13, [22] [23] [24] [25] The modulation of STAT1 signaling, central regulator of ISGs, by a phosphorylation-acetylation switch reflects the importance of HDAC activity on the response to IFN. 26 Hence, this study analyzed selected SNPs in HDACs in relation to the achievement of an SVR to peg-IFN-based therapy, finding a significant and additive enhancement of the IL-28B predictive value by combined HDAC2 (rs3778216), HDAC3 (rs976552) and HDAC5 (rs368328) genotyping (AUC ¼ 0.630 vs AUC ¼ 0.679; Sen ¼ 43% vs Sen ¼ 56% and Sp ¼ 83% vs Sp ¼ 75.5%). The addition of those SNPs to the IL-28B model significantly improved its accuracy; even more, once all SVR-related variables were taken into account, a precise model of response could be built, reaching the best sensitivity (75%) and predictive value (AUC ¼ 0.776), despite a slight decrease on specificity (70%) comparing to the IL-28B model. Since lost opportunity of treatment involves great risk of CHC progression to cirrhosis and HCC, the considerable improvement on sensitivity obtained by the addition of HDACs genotyping to the IL-28B model highlights the relevance of their characterization if validated.
Despite the suggested functional redundancy of HDACs, the rs3778216 and rs976552 genetic variants notably influenced the outcome of IFN-based treatments. Because HDAC activity elicits antiviral responses through IFNa signaling by the JAK-STAT pathway, 14, 27 the characterized rs3778216 and rs976552 SNPs lying in HDAC2 non-coding region and HDAC3 5 0 near gene, which might influence gene expression, could explain the differences in SVR rates.
The role of HDACs on liver pathophysiology has been well documented-disruption of HDAC3 is linked to the dysregulation of hepatic lipid homeostasis, 28 a hallmark of CHC. Moreover, altered HDAC2 and 3 expression and copy number gains are related to HCC development and survival. 16, 17 In addition to the HDAC2 and HDAC3 SNPs above, a polymorphism in HDAC5 was also independently associated with the achievement of an SVR (rs368328). The intronic location of rs368328, which might affect RNA processing or protein expression, could account for the differential CHC responses to IFN-based therapy.
It must be noted that the tagSNPs significantly related to SVR, rs3778216 and rs368328, are in strong linkage disequilibrium (r 2 40.8) with other 11 and 15 genetic variants in HDAC2 and HDAC5, respectively (Supplementary Table 3) ; thus, any of those SNPs might be involved in the observed effect. Furthermore, indepth analysis of candidate genes avoids missing true-positive related genetic variants frequently hidden in genome-wide association studies owing to the required restrictive statistics. ).
HDACs and IL-28B SNPs on CHC therapy response R Ló pez-Rodríguez et al
By hierarchy analysis of all variables independently associated with SVR, the classification of CHC patients on the basis of their likelihood to respond to combination treatment improved substantially. Whereas IL-28B, age, HDAC2 and HDAC5 were relevant for decision making (CHAID analysis), HDAC3 and BVL were excluded from the model. Notably, the response to treatment enhanced significantly in patients with both favorable IL-28B and HDAC2 genotypes (P c ¼ 0.017). Patients with the C/C genotype of IL-28B achieved an SVR more frequently when they also carried the C/C genotype of HDAC2 (88.9% vs 77.6%). Patients who harbored the T allele of the HDAC2 SNP had lower SVR rates despite carrying the C/C genotype of IL-28B (64.5% vs 77.6%); nonetheless, combination treatment could be still worthy in this subgroup of patients due to its acceptable SVR rate (around 65%) as these preliminary results suggest.
However, combined genotyping identified a subgroup of CHC patients aged under 40 years who were good virological responders despite bearing the undesirable T allele of IL-28B (79.2% chance of response vs 48.3%). Thus, many patients who are initially ineligible for peg-IFN plus ribavirin therapy, based on IL-28B genotyping, might receive substantial benefits from this therapy if they also carry the HDAC2 C/C genotype (over 10% of the study population). Hence, combination genotyping of IL-28B and HDAC2 SNPs might facilitate treatment decisions by physicians if these results are further validated.
On the other hand, patients aged over 40 years who carried undesirable T and G alleles in IL-28B and HDAC5, respectively, did not benefit from IFN-based treatment because only one-quarter of this subgroup (6% of our CHC population) is expected to achieve an SVR (P c ¼ 0.003). Thus, on the basis of these preliminary data, they would be encouraged to wait for future therapies to avoid adverse events and futile outlays.
Further analysis, adjusted for viral genotype, showed similar results for HCV-1 patients, in which HDAC2, HDAC3 and HDAC5 SNPs in addition to rs12979860, identified those with a greater chance of attaining an SVR. Interestingly, the association of rs12979860 with SVR in non-HCV-1 was lost after multivariate regression analysis, being the rs3778216 in HDAC2 the strongest predictive factor of SVR in non-HCV-1 patients (P ¼ 0.007 and AUC ¼ 0.733). To our knowledge, this is the first genetic variant, distinct of IL-28B, which significantly predicts SVR of non-HCV-1 patients. 30, 31 According to previous results performed in two huge cohorts of HCV-2/3 patients, 32, 33 in our group of non-HCV-1 patients (n ¼ 56) IL-28B C/C genotype did not retain predictive SVR value. As shown, the SVR was improved by rs3778216 genotyping from 75% (based solely on viral genotype) to 92.3% for C/C carriers of this SNP, which corresponds to nearly 50% of Figure 3 . Decision tree model of response to CHC treatment, calculated by the CHAID algorithm. The hierarchy model included IL-28B, HDAC2, age and HDAC5 as significant factors for treatment decision. Pie charts indicate the rate (%) of response (black) and non-response (gray) in each group of patients after splitting for each factor. The number of patients and the percentage that is represented in the overall population are indicated under each pie chart. P c : corrected P-value.
our non-HCV-1 subjects and 10% of the total CHC cohort (CHAID, data not shown). Thus, our findings might help specify CHC therapy in this subgroup of patients, but should be considered with caution because of the restricted sample size of this subpopulation.
In conclusion, herein preliminary data indicate the value of certain HDAC genetic variants as independent pretreatment predictors of the response to combination therapy in CHC, improving treatment strategies based on IL-28B genotyping. HDAC2 and HDAC5 genotyping better characterizes CHC patients according to their likelihood of SVR. Furthermore, HDAC2 rs3778216 is an important novel putative genetic variant in the prognosis of treatment outcomes in CHC patients who are infected by non-HCV-1. Thus, if validated, combination genotyping of IL-28B and HDACs should effect more accurate pretreatment decisions, optimizing and tailoring CHC antiviral therapies.
MATERIALS AND METHODS

Patients and study design
The study cohort comprised 285 Caucasian patients from three university hospitals in Spain (La Princesa, Madrid; San Cecilio, Granada; and Central de Asturias, Oviedo, Spain). The protocol was approved by the ethics committees of all hospitals, and all patients gave written informed consent before enrollment.
Patients had a previous diagnosis of HCV infection and had received peg-IFNa 2a or 2b plus ribavirin, adjusted for body weight. HCV status was confirmed, based on the presence of detectable HCV RNA in the serum (COBAS AMPLICOR assay; Roche Diagnosis GmbH, Mannheim, Germany). HCV genotype was determined by reverse hybridization (Inno-LIPA II HCV; Innogenetics SA, Ghent, Belgium). Treatment duration was 24 or 48 weeks, depending on HCV genotype. SVR was defined as undetectable HCV RNA in the serum 6 months after completion of therapy. No patient showed evidence of HBV, HIV, alcoholism, autoimmunity or drug-induced liver disease.
SNP selection and genotyping
SNPs in the 11 HDAC genes were selected by their tagSNP condition (tagSNPs capture most of the genetic variation in a region) or location in key regulatory regions, as described in the HapMap project, Release no. 27, Phase II and III (www.hapmap.org) for the CEU population (Utah residents with Northern and Western European ancestry from the CEPH collection). The specific location of each SNP (coding/non-coding region and chromosomal position) is detailed in Supplementary Table 1. SNPs with an estimated minor allele frequency of p5%, an estimated r 2 o0.8 between two SNPs in the same gene or with low predicted quality for being genotyped were discarded. Twenty-seven SNPs that met these criteria, which are able to capture 63 SNPs (r 2 40.8; Supplementary  Table 3) , were genotyped by GoldenGate Genotyping Assay (Illumina Inc., San Diego, CA, USA) at CICbioGUNE (Center for Cooperative Research in Biosciences, Vizcaya, Spain). In addition, the IL-28B rs12979860 was genotyped by polymerase chain reaction, as described. 4 
Statistical analysis
Hardy-Weinberg equilibrium and genotype/haplotype frequencies were calculated using SNPStats. 34 The association between SNPs and SVR was determined by logistic regression analysis and expressed as odds ratio, 95% confidence interval and P-value (SPSS version 15.0; SPSS Inc., Chicago, IL, USA).
Subsequently, all significant variables (Po0.05) were analyzed by multivariate logistic regression using a step-backward method, in which none of the variables was forced to be included into the model. Next, ROC analyses were performed to discriminate the power of factors independently associated with SVR. Statistical differences between the AUCs of factors were analyzed by Hanley and McNeil test using the MedCalc software, version 11.6.1.0 (Mariakerke, Belgium).
Finally, a decision tree model was built using the CHAID algorithm, which uses the statistical significance from w 2 tests to establish a hierarchy of risk factors, to select the best host and viral factors for classifying patients into SVR or non-response subgroups. The CHAID algorithm automatically removes factors that are not statistically significant. A P-value o0.05 after CHAID correction for multiple testing was considered significant (Pc).
